TY - JOUR
T1 - Determination of nalbuphine by high-performance liquid chromatography with ultraviolet detection
T2 - Application to human and rabbit pharmacokinetic studies
AU - Ho, Shung Tai
AU - Wang, Jhi Joung
AU - Hu, Oliver Yoa Pu
AU - Chiang, Pei Shan
AU - Lee, Shih Chun
PY - 1996/4/12
Y1 - 1996/4/12
N2 - A rapid, sensitive, precise and accurate high-performance liquid chromatographic assay with ultraviolet detection was developed for the determination of nalbuphine in human, rabbit, pig and dog plasma. It is comprised of only a one-step extraction procedure with hexane-isoamyl alcohol at pH 9.25 and reversed-phase chromatography on a μPorasil column. The recoveries of nalbuphine and ethylmorphine (internal standard) were greater than 86%. Calibration graphs were linear over the concentration range 0.75-150 ng/ml with a coefficient of variation, both within-day and between-day, of less than 10% at any level. The limit of quantitation was 0.75 ng/ml of plasma based on a signal-to-noise ratio of 3. Seven other clinically used analgesics were investigated to check for potential interferences and their analytical conditions. The specificity of this assay was checked with a metabolite of nalbuphine (noroxymorphine). Nalbuphine in plasma did not decompose significantly at -20°C for six weeks. Pharmacokinetic application in three surgical patients and four rabbits revealed that nalbuphine followed a linear three-compartment model with two distribution phases. The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.
AB - A rapid, sensitive, precise and accurate high-performance liquid chromatographic assay with ultraviolet detection was developed for the determination of nalbuphine in human, rabbit, pig and dog plasma. It is comprised of only a one-step extraction procedure with hexane-isoamyl alcohol at pH 9.25 and reversed-phase chromatography on a μPorasil column. The recoveries of nalbuphine and ethylmorphine (internal standard) were greater than 86%. Calibration graphs were linear over the concentration range 0.75-150 ng/ml with a coefficient of variation, both within-day and between-day, of less than 10% at any level. The limit of quantitation was 0.75 ng/ml of plasma based on a signal-to-noise ratio of 3. Seven other clinically used analgesics were investigated to check for potential interferences and their analytical conditions. The specificity of this assay was checked with a metabolite of nalbuphine (noroxymorphine). Nalbuphine in plasma did not decompose significantly at -20°C for six weeks. Pharmacokinetic application in three surgical patients and four rabbits revealed that nalbuphine followed a linear three-compartment model with two distribution phases. The two distribution and one elimination half-lives and the plasma clearance of nalbuphine were 0.9, 5.8 and 157 min and 370 ml/min in human, and 3.5, 28 and 117 min and 21 166 ml/min in rabbits.
KW - Nalbuphine
UR - http://www.scopus.com/inward/record.url?scp=0030005547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030005547&partnerID=8YFLogxK
U2 - 10.1016/0378-4347(95)00477-7
DO - 10.1016/0378-4347(95)00477-7
M3 - Article
C2 - 8738033
AN - SCOPUS:0030005547
SN - 1572-6495
VL - 678
SP - 289
EP - 296
JO - Journal of Chromatography B: Biomedical Applications
JF - Journal of Chromatography B: Biomedical Applications
IS - 2
ER -